BioLineRx (BLRX) Change in Acquisitions & Divestments (2013 - 2025)

BioLineRx's Change in Acquisitions & Divestments history runs 13 years deep, the most recent figure standing at -$7.6 million for Q4 2025.

• On a quarterly basis, Change in Acquisitions & Divestments changed N/A year-over-year to -$7.6 million in Q4 2025; TTM through Dec 2025 was -$36.6 million, a 39.07% decrease from a year earlier, with the FY2025 full-year figure at -$36.6 million, down 39.07% from the prior year.
• Change in Acquisitions & Divestments retreated to -$7.6 million in Q4 2025 per BLRX's latest filing, from -$4.2 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $16.7 million in Q1 2024 and bottomed at -$42.0 million in Q1 2021.
• The 5-year median for Change in Acquisitions & Divestments is -$8.0 million (2021), against an average of -$12.2 million.
• Biggest YoY gain for Change in Acquisitions & Divestments was 403.98% in 2024; the steepest drop was 7267.19% in 2024.
• Year by year, Change in Acquisitions & Divestments stood at -$8.0 million in 2021, then changed by 0.0% to -$8.0 million in 2022, then plunged by 321.32% to -$33.7 million in 2023, then jumped by 82.82% to -$5.8 million in 2024, then slumped by 31.53% to -$7.6 million in 2025.
• Per Business Quant, the three latest BLRX Change in Acquisitions & Divestments figures stand at -$7.6 million (Q4 2025), -$4.2 million (Q3 2025), and -$12.5 million (Q2 2025).